Studies of NSCLC patients treated with anti-PD-1/PD-L1 agents have characterised and quantified total ctDNA by determining allele fraction of cancer-associated somatic mutations in blood plasma using an NGS gene-panel approach. The gene discussed is CD274; the disease is cancer.